Moncef Slaoui | Medicxi

Moncef is a Partner at Medicxi and has been with the firm since September 2017. He currently serves on the board of Divide & Conquer, Monopteros and has an active role in several other Medicxi portfolio companies to support their development. 

Prior to Medicxi, Moncef was GlaxoSmithKline’s Head of Pharmaceutical R&D and Chairman of its Vaccines division.  From this leadership role, Moncef spearheaded a profound overhaul of GSK's pharmaceutical R&D, resulting in a substantial improvement in productivity, a late-stage pipeline comprising more than 30 phase 3 programmes and a totally redesigned discovery organisation comprising 38 highly focused and accountable Discovery Performance Units. During his career at GSK, he also headed the development of a robust vaccines pipeline, including Rotarix to prevent infantile gastroenteritis, Synflorix to prevent pneumococcal disease and Cervarix to prevent cervical cancer.

Outside of his role at Medicxi, Moncef is chairman of the board at Galvani Bioelectronics, chairman of the board at SutroVax and sits on the boards of Artisan Biosciences, Human Vaccines Project and Moderna Therapeutics.

Moncef received a PhD in Molecular Biology and Immunology from the Université Libre de Bruxelles, Belgium and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston. He was a professor of Immunology at the University of Mons, Belgium and has authored more than 100 scientific papers and presentations. A citizen of Morocco, Belgium and the USA, he is fluent in English, French and Arabic.